Abeona Therapeutics (NASDAQ:ABEO) CEO Sells $169,154.80 in Stock

Posted by George Bondi on Jun 12th, 2026

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) CEO Vishwas Seshadri sold 31,916 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.30, for a total value of $169,154.80. Following the completion of the transaction, the chief executive officer directly owned 1,374,079 shares of the company’s stock, valued at $7,282,618.70. This represents a 2.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vishwas Seshadri also recently made the following trade(s):

On Monday, June 8th, Vishwas Seshadri sold 24,428 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.43, for a total value of $132,644.04.

Abeona Therapeutics Stock Up 3.2%

Shares of NASDAQ:ABEO opened at $5.53 on Friday. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $5.42 and a two-hundred day simple moving average of $5.17. Abeona Therapeutics Inc. has a 12-month low of $4.00 and a 12-month high of $7.54. The stock has a market capitalization of $315.15 million, a price-to-earnings ratio of 5.70 and a beta of 1.35.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $8.72 million during the quarter, compared to the consensus estimate of $4.57 million. On average, research analysts anticipate that Abeona Therapeutics Inc. will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc purchased a new stake in Abeona Therapeutics during the 2nd quarter valued at $27,000. Royal Bank of Canada boosted its stake in Abeona Therapeutics by 49.6% during the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 2,155 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Abeona Therapeutics during the 3rd quarter valued at $37,000. Truvestments Capital LLC boosted its stake in Abeona Therapeutics by 191.4% during the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 6,770 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Abeona Therapeutics during the 4th quarter valued at $57,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a report on Tuesday, March 17th. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $19.00.

Read Our Latest Stock Report on Abeona Therapeutics

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.